A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Recruiting now · Phase 2

Conditions studied: Advanced Lung Cancer

In brief

This is a multicenter, open-label Phase II clinical study, with the main objective being to evaluate the investigator-assessed objective response rate of JS212 in combination therapy for advanced lung cancer. The aim is to explore the safety, tolerability, and preliminary efficacy of JS212 combined with JS207, Toripalimab, JS213 combined or not combined with chemotherapy.

Key facts

Study ID

NCT07309276

Run by

Shanghai Junshi Bioscience Co., Ltd.

People needed

864

Starts

2026-01-23

Expected to finish

2028-11-11

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The age between 18 and 75 years old, and any gender.
• Local advanced, metastatic or recurrent NSCLC.
• ES-SCLC.
• According to the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1), there must be at least one measurable lesion.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
• Expected survival period of ≥ 12 weeks.
• The functions of important organs meet the requirements.
• Female participants with reproductive capacity (WOCBP) who have sexual life with an unsterilized male partner and who have signed the informed consent must have a negative serum pregnancy test result within 7 days before the first administration, and must agree to take effective contraceptive measures from the time of signing the ICF until 7 months after the last administration of the study.
• Unsterilized male participants who have sexual life with a fertile female partner must agree to use the effective contraceptive measures after signing the ICF until 4 months after the last administration of the study. During this period, sperm donation is prohibited.
• The participants voluntarily participate in this study and sign the informed consent.

You may not qualify if…

• Accompanying the following disease states:
• Tumor histological or cytological pathological confirmation of combined large cell neuroendocrine carcinoma or sarcomatoid lesion, or NSCLC with small cell lung cancer component;
• NSCLC patients with positive driver mutations;
• Patients with known meningeal metastasis;
• Patients with symptomatic brain metastases;
• Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites;
• Unatable spinal cord compression;
• Participants in Cohort 1 and Cohort 4 need to exclude any of the following conditions:
• Within one month before the first use of the study drug, any clinically significant hemoptysis or tumor bleeding;
• High bleeding risk; tumor invading important organs, high risks of perforation, esophageal-tracheal fistula, massive hemoptysis, etc.;
• Obvious bleeding tendency or severe coagulation dysfunction history, etc;
• Recent gastrointestinal perforation, gastrointestinal obstruction, trachea-esophageal fistula, abdominal fistula or intra-abdominal abscess, or currently having high-risk factors for hollow organ perforation/ fistula formation, or active inflammatory bowel disease, etc;
• Presence of severe, non-healed or open wounds, active ulcers or untreated fractures;
• Have poorly controlled hypertension;
• Have used antiplatelet drugs or anticoagulant therapy within 14 days;
• Have experienced a drug-related adverse event that led to permanent discontinuation of the medication during previous Bevacizumab and similar agent treatments;
• Have received any of the following treatments:
• Immune-mediated treatments (only for part Two);
• Have received any investigational drug within 4 weeks or 5 half-lives before the first use of the study drug;
• Have been enrolled in another clinical study;
• Have undergone major surgery within 4 weeks;
• Have received local small-scale radiotherapy within 14 days;
• Have not recovered to ≤ CTCAE grade 1 toxicity or the level specified in the inclusion/exclusion criteria.
• Have known allergies to any study treatment or its excipients or have experienced an allergic reaction.
• Have experienced a drug-related AE that led to permanent discontinuation of the anti-PD-(L)1 antibody treatment.

Where it is running

• Shanghai East Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.